Huisman Mv
About
In The Last Decade
Huisman Mv
16 papers receiving 194 citations
Peers
Comparison fields: 5 of 35
- Internal Medicine 143
- Hematology 86
- Cardiology and Cardiovascular Medicine 65
- Surgery 65
- Emergency Medical Services 61
Countries citing papers authored by Huisman Mv
This map shows the geographic impact of Huisman Mv's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Huisman Mv with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Huisman Mv more than expected).
Fields of papers citing papers by Huisman Mv
This network shows the impact of papers produced by Huisman Mv. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Huisman Mv. The network helps show where Huisman Mv may publish in the future.
Co-authorship network of co-authors of Huisman Mv
This figure shows the co-authorship network connecting the top 25 collaborators of Huisman Mv. A scholar is included among the top collaborators of Huisman Mv based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Huisman Mv. Huisman Mv is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 1 | |
| 2 | [Pulmonary embolism response teams: what is the added value for patients with acute pulmonary embolism?] | 1 |
| 3 | embolism: a meta-analysis | 1 |
| 4 | [Suspicion of pulmonary embolism: added value of CT depends on patient characteristics and referring individual]. | 3 |
| 5 | [Right-ventricular dysfunction and the pulmonary vascular obstruction index: predictable variables of the clinical course over 3 months in patients with acute lung emboli]. | 4 |
| 6 | Treatment of acute, symptomatic, proximal deep vein thrombosis with the oral, direct Factor Xa inhibitor rivaroxaban (BAY 59-7939) - the ODIXa-DVT dose-ranging study | 9 |
| 7 | The contribution of factor V Leiden and prothrombin G20210A mutation to the risk of central venous catheter-related thrombosis. | 59 |
| 8 | 1 | |
| 9 | [Protocol for ambulant treatment of deep venous thrombosis in a leg: efficacious and safe in general practice]. | 2 |
| 10 | Clinical evaluation of a monoclonal antibody-based enzyme immunoassay for fibrin degradation products in patients with clinically suspected pulmonary embolism. ANTELOPE-Study Group. | 3 |
| 11 | 65 | |
| 12 | [Thromboembolic complications of central venous catheters]. | 1 |
| 13 | Mechanical prophylaxis of deep vein thrombosis. | 5 |
| 14 | 40 | |
| 15 | 3 | |
| 16 | [Evaluation of the consensus deep venous thrombosis]. | 1 |
| 17 | [Cost-benefit analysis of the diagnosis of patients with deep venous thrombosis]. | 1 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.